Companies › NovaRock Biotherapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NBL-020 for Injection | – | Phase 1 | Advanced Malignant Tumors | Dec 2026 |
| NBL-028 anti-CLDN6 antibody-drug conjugate | CLDN6 | Phase 1 | Advanced Solid Tumor | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05877924 | NBL-020 for Injection | Phase 1 | Advanced Malignant Tumors | Oncology | Dec 2026 |
| NCT06223256 | NBL-028 | Phase 1 | Advanced Solid Tumor | Oncology | Jan 2027 |
BioNTech Cell & Gene Therapies Context Therapeutics BeOne Medicines
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.